MAP2K7 and eye disorder: Eye disorders are considered a class effect of MEK inhibitors [12–14] and were reported as AEs with dabrafenib plus trametinib combination therapy in international phase III trials (COMBI-d and COMBI-v) [16, 17] and in a PMS of Japanese patients with malignant melanoma [15].